
FDA Expands Orphan Drug Designation for SurVaxM, Immunotherapy Developed at Roswell Park
FDA Expands Orphan Drug Designation for SurVaxM, Immunotherapy Developed at Roswell Park
Orphan status for cancer treatment vaccine now applies to use to treat malignant gliomas in children and adults
Details
More Products & Services
People

Kimberly Sweeney
Roswell Park Comprehensive Cancer Center
Vice President of Patient Experience

Sai Yendamuri
Roswell Park Comprehensive Cancer Center
Chief Strategy Officer; SVP of Business Development & Outreach; Chair of Thoracic Surgery

Shashi Lele
Roswell Park Comprehensive Cancer Center
Medical Director, International Patients

Sunita Panesar
Roswell Park Comprehensive Cancer Center
Vice President of Strategy, Business Development & Outreach
Description
HIGHLIGHTS
- New designation broadens potential use of vaccine as treatment for glioma
- Nationwide trials continue in adults, children with some brain tumors
- Development of SurVaxM made possible by community donations
- New designation broadens potential use of vaccine as treatment for glioma
- Nationwide trials continue in adults, children with some brain tumors
- Development of SurVaxM made possible by community donations

Share
Recent Chats
Share via email
Future: handle WhatsApp here
Future: handle LinkedIn here
Future: handle Twitter here
SUBMENU HERE
Share via Chat
Copy Link